Innovent Biologics

Innovent Biologics To empower patients worldwide with affordable, high-quality biopharmaceuticals Innovent has launched 11 products in the market.

Innovent is a leading biopharmaceutical company founded in 2011 with the mission to empower patients worldwide with affordable, high-quality biopharmaceuticals. The company discovers, develops, manufactures and commercializes innovative medicines that target some of the most intractable diseases. Its pioneering therapies treat cancer, cardiovascular and metabolic, autoimmune and eye diseases. It has 5 new drug applications under regulatory review, 3 assets in Phase III or pivotal clinical trials and 18 more molecules in early clinical stage. Innovent partners with over 30 global healthcare companies, including Eli Lilly, Sanofi, Incyte, Adimab, LG Chem and MD Anderson Cancer Center. Guided by the motto, “Start with Integrity, Succeed through Action,” Innovent maintains the highest standard of industry practices and works collaboratively to advance the biopharmaceutical industry so that first-rate pharmaceutical drugs can become widely accessible. For more information, visit www.innoventbio.com, or follow Innovent on Facebook and LinkedIn.

On World Diabetes Day, Innovent stands with the global community to raise awareness of diabetes and its impact, especial...
14/11/2025

On World Diabetes Day, Innovent stands with the global community to raise awareness of diabetes and its impact, especially in the workplace. 589 million adults worldwide live with diabetes, and 7 in 10 are of working age, with many experiencing burnout, anxiety, or depression, highlighting the personal and societal challenges of this condition.

Metabolic diseases such as overweight and obesity are closely linked to type 2 diabetes, increasing the risk of serious health complications. In China, over 500 million adults live with overweight or obesity, many with related metabolic conditions, underscoring the urgent need for supportive environments and effective solutions. Mazdutide, our self-developed GCG/GLP-1 dual receptor agonist, is one example of an innovative therapy addressing these interconnected challenges.

Today, we reaffirm our commitment to supporting initiatives that improve awareness, empower individuals, and promote well-being, joining global efforts to combat diabetes and its impact on people's lives.


We're excited to share Phase 1 clinical data for IBI3016, a first-in-human siRNA therapy targeting AGT mRNA, presented a...
12/11/2025

We're excited to share Phase 1 clinical data for IBI3016, a first-in-human siRNA therapy targeting AGT mRNA, presented at the AHA 2025 Scientific Sessions. In this single-dose, randomized, placebo-controlled study, IBI3016 demonstrated sustained and potent AGT mRNA suppression with preliminary antihypertensive effects and a favorable safety profile. These encouraging results support the potential for twice-yearly subcutaneous dosing in hypertension and reflect meaningful progress in our general biomedicine pipeline as we work to advance innovative RNA-based treatment options for patients. https://www.prnewswire.com/news-releases/innovent-and-sanegenebio-announce-phase-1-clinical-data-for-ibi3016-presented-at-american-heart-association-aha-2025-annual-meeting-302609412.html


New preclinical data from our general biomedicine pipeline was presented at the 2025 American College of Rheumatology An...
12/11/2025

New preclinical data from our general biomedicine pipeline was presented at the 2025 American College of Rheumatology Annual Meeting, including results for IBI3011 (IL-1RAP monoclonal antibody) showing inhibition of IL-1/IL-33/IL-36–driven inflammatory pathways and IBI3034 (TACI/BCMA chimeric fusion protein) demonstrating potent modulation of B cells and serum immunoglobulin levels. These data highlight continued momentum in advancing innovative therapies for autoimmune and inflammatory diseases.

Read more in our full announcement:https://www.prnewswire.com/news-releases/multiple-research-results-from-innovents-general-biomedicine-pipeline-showcased-at-2025-acr-annual-meeting-302603902.html

Today, we join the global community in recognizing World Psoriasis Day, to raise awareness, encourage action, and suppor...
29/10/2025

Today, we join the global community in recognizing World Psoriasis Day, to raise awareness, encourage action, and support people living with psoriatic disease.

This year's theme underscores an important message: Psoriasis is more than just a skin condition; it is a systemic inflammatory disease that can impact long-term health, including cardiovascular, metabolic, and mental well-being.

At Innovent, we remain committed to advancing scientific understanding and exploring new therapeutic approaches, including research in biologic switching for patients with difficult-to-treat psoriasis. Our goal is to help address unmet medical needs and support better quality of life for those affected.

We are pleased to share positive topline results from our Phase 3 DREAMS-3 trial of mazdutide, a first-in-class GLP-1/GC...
28/10/2025

We are pleased to share positive topline results from our Phase 3 DREAMS-3 trial of mazdutide, a first-in-class GLP-1/GCG dual receptor agonist. In this head-to-head study, 48% of participants treated with mazdutide achieved both HbA1c

Innovent Biologics is proud to announce a global strategic partnership with Takeda, marking one of the most significant ...
24/10/2025

Innovent Biologics is proud to announce a global strategic partnership with Takeda, marking one of the most significant collaborations in our history. Together, we will accelerate the worldwide development of Innovent's next-generation immuno-oncology (IO) backbone therapy and antibody-drug conjugate (ADC) programs.

This collaboration unites Innovent's proven IO and ADC R&D capabilities with Takeda's world-class expertise in advancing and commercializing oncology medicines globally. It reflects a shared vision and steadfast commitment to advancing transformative therapies for patients worldwide.

Learn more about the partnership here:https://www.prnewswire.com/news-releases/innovent-biologics-announces-global-strategic-partnership-with-takeda-to-bring-innovents-next-gen-io-backbone-therapy-and-adc-molecules-to-the-global-market-302590770.html

We're happy to share that the NMPA has approved a second indication for mazdutide—for glycemic control in adults with ty...
20/09/2025

We're happy to share that the NMPA has approved a second indication for mazdutide—for glycemic control in adults with type 2 diabetes!

As the world's first dual GCG/GLP-1 receptor agonist approved for T2D, mazdutide provides comprehensive benefits across glycemic control, weight reduction, and hepato-cardio-renal health. This approval expands treatment options for China's 140 million adults living with T2D and supports the vision of Healthy China 2030.

https://www.prnewswire.com/news-releases/innovent-announces-mazdutide-received-approval-from-chinas-nmpa-for-glycemic-control-in-adults-with-type-2-diabetes-302561434.html?tc=eml_cleartime

We're excited to present multiple research results at in Paris!Our findings, including post hoc analyses of Phase 2 an...
17/09/2025

We're excited to present multiple research results at in Paris!

Our findings, including post hoc analyses of Phase 2 and 3 clinical studies of IBI112 (IL-23p19 monoclonal antibody, picankibart), as well as preclinical study results for IBI3013 (IL-15 monoclonal antibody) and IAR129 (IL-4R/OX40L bispecific antibody), will be showcased in seven ePosters.
https://www.prnewswire.com/news-releases/innovent-to-present-multiple-rd-results-of-general-biomedicine-pipeline-at-the-34th-eadv-congress-2025-302556355.html?tc=eml_cleartime

Innovent has been awarded the MSCI-ESG AAA rating for the second consecutive year, underscoring our ability to sustain e...
12/09/2025

Innovent has been awarded the MSCI-ESG AAA rating for the second consecutive year, underscoring our ability to sustain excellence in governance, innovation, and responsibility amid a rapidly changing global landscape. By embedding ESG into our corporate DNA, we continue to link scientific innovation with sustainable development for the benefit of patients, partners, and society.

Innovent announced new data at the 2025 APLAR Congress showing that tigulixostat (IBI128), an investigational xanthine o...
08/09/2025

Innovent announced new data at the 2025 APLAR Congress showing that tigulixostat (IBI128), an investigational xanthine oxidase inhibitor, achieved significantly greater urate-lowering efficacy and favorable safety across all dose groups compared to febuxostat in a Phase 2 study of Chinese gout participants. Building on these positive results, we plan to initiate a Phase 3 clinical study of tigulixostat in China in the second half of 2025. https://www.prnewswire.com/news-releases/innovent-announces-phase-2-results-of-tigulixostat-ibi128-xoi-in-gout-patients-were-published-at-the-27th-asia-pacific-league-of-associations-for-rheumatology-congress-302548517.html?tc=eml_cleartime

05/09/2025

Our CFO, Rachel You, joined Bloomberg TV to discuss Innovent’s 2025 interim results and share insights into our strategy for sustainable growth. She highlighted the strong early performance of mazdutide, our GCG/GLP-1 receptor agonist obesity therapy, and the progress of our expanding pipeline. We invite you to watch the full interview to learn more about what’s ahead for our business and innovation journey.

Address

Suzhou
215028

Telephone

+8651269566088

Website

Alerts

Be the first to know and let us send you an email when Innovent Biologics posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to Innovent Biologics:

Shortcuts

Share

Share on Facebook Share on Twitter Share on LinkedIn
Share on Pinterest Share on Reddit Share via Email
Share on WhatsApp Share on Instagram Share on Telegram

Category